BioSpace News Archive

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12th Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023.

CardieX Limited today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that its founder, President and Interim Chief Executive Officer, Thomas Gad, will provide an overview and update on the Company’s business at the virtual 41st Annual J.P. Morgan Healthcare Conference.

Aditxt, Inc. announces the formation of a U.S.-based subsidiary Adimune, Inc. and its plans towards submission of a Clinical Trial Application for its immunotherapeutic technology drug candidate, ADI™-100.

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, will showcase TempTraq® at the 2023 Consumer Electronics Show at the Las Vegas Convention Center January 5-8.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia’s U.S. Patent No. 10,286,036.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reports that it has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for afami-cel for use as a single-dose regimen for the treatment of advanced synovial sarcoma.

Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the “Consulting Agreement”) with Mr. Adam Smith of Red Cloud Securities Inc. (“Red Cloud”) to support Marvel’s market stabilization and liquidity activities.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

CNS Pharmaceuticals, Inc. announced it has appointed Faith L. Charles as Chair of its Board of Directors.